![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GALNT2 |
Gene summary for GALNT2 |
![]() |
Gene information | Species | Human | Gene symbol | GALNT2 | Gene ID | 2590 |
Gene name | polypeptide N-acetylgalactosaminyltransferase 2 | |
Gene Alias | CDG2T | |
Cytomap | 1q42.13 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | B7Z6K2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2590 | GALNT2 | CCI_1 | Human | Cervix | CC | 1.63e-03 | 6.17e-01 | 0.528 |
2590 | GALNT2 | CCI_2 | Human | Cervix | CC | 1.23e-04 | 6.88e-01 | 0.5249 |
2590 | GALNT2 | CCI_3 | Human | Cervix | CC | 6.13e-24 | 1.52e+00 | 0.516 |
2590 | GALNT2 | EEC-subject3 | Human | Endometrium | EEC | 2.37e-05 | 1.93e-01 | -0.2525 |
2590 | GALNT2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.06e-14 | 3.08e-01 | -0.1869 |
2590 | GALNT2 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 1.40e-10 | 2.40e-01 | -0.1875 |
2590 | GALNT2 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 7.60e-11 | 1.26e-01 | -0.1883 |
2590 | GALNT2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 4.18e-15 | 2.75e-01 | -0.1934 |
2590 | GALNT2 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.66e-16 | 2.62e-01 | -0.1917 |
2590 | GALNT2 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.92e-19 | 3.66e-01 | -0.1916 |
2590 | GALNT2 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 8.10e-03 | 2.84e-01 | -0.1269 |
2590 | GALNT2 | LZE2D | Human | Esophagus | HGIN | 1.15e-02 | 2.88e-01 | 0.0642 |
2590 | GALNT2 | LZE4T | Human | Esophagus | ESCC | 3.26e-13 | 3.45e-01 | 0.0811 |
2590 | GALNT2 | LZE5T | Human | Esophagus | ESCC | 2.60e-04 | 1.06e-01 | 0.0514 |
2590 | GALNT2 | LZE7T | Human | Esophagus | ESCC | 4.66e-06 | 2.06e-01 | 0.0667 |
2590 | GALNT2 | LZE8T | Human | Esophagus | ESCC | 1.07e-07 | 8.81e-02 | 0.067 |
2590 | GALNT2 | LZE20T | Human | Esophagus | ESCC | 4.52e-02 | 2.26e-01 | 0.0662 |
2590 | GALNT2 | LZE22D1 | Human | Esophagus | HGIN | 1.19e-04 | 1.64e-01 | 0.0595 |
2590 | GALNT2 | LZE22T | Human | Esophagus | ESCC | 1.67e-07 | 4.17e-01 | 0.068 |
2590 | GALNT2 | LZE24T | Human | Esophagus | ESCC | 6.53e-17 | 5.14e-01 | 0.0596 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00182096 | Cervix | CC | peptidyl-serine modification | 66/2311 | 338/18723 | 9.58e-05 | 1.25e-03 | 66 |
GO:00516048 | Cervix | CC | protein maturation | 56/2311 | 294/18723 | 5.90e-04 | 5.59e-03 | 56 |
GO:00182106 | Cervix | CC | peptidyl-threonine modification | 26/2311 | 125/18723 | 4.98e-03 | 2.97e-02 | 26 |
GO:0018279 | Colorectum | AD | protein N-linked glycosylation via asparagine | 15/3918 | 23/18723 | 5.47e-06 | 1.40e-04 | 15 |
GO:0018196 | Colorectum | AD | peptidyl-asparagine modification | 15/3918 | 24/18723 | 1.18e-05 | 2.62e-04 | 15 |
GO:0030258 | Colorectum | AD | lipid modification | 67/3918 | 212/18723 | 1.66e-04 | 2.27e-03 | 67 |
GO:0006487 | Colorectum | AD | protein N-linked glycosylation | 25/3918 | 65/18723 | 9.12e-04 | 8.71e-03 | 25 |
GO:0009225 | Colorectum | AD | nucleotide-sugar metabolic process | 16/3918 | 36/18723 | 1.27e-03 | 1.12e-02 | 16 |
GO:0006486 | Colorectum | AD | protein glycosylation | 64/3918 | 226/18723 | 4.86e-03 | 3.27e-02 | 64 |
GO:0043413 | Colorectum | AD | macromolecule glycosylation | 64/3918 | 226/18723 | 4.86e-03 | 3.27e-02 | 64 |
GO:0070085 | Colorectum | AD | glycosylation | 67/3918 | 240/18723 | 5.78e-03 | 3.67e-02 | 67 |
GO:0007162 | Colorectum | SER | negative regulation of cell adhesion | 68/2897 | 303/18723 | 8.02e-04 | 1.01e-02 | 68 |
GO:00182791 | Colorectum | SER | protein N-linked glycosylation via asparagine | 9/2897 | 23/18723 | 5.20e-03 | 3.95e-02 | 9 |
GO:00302581 | Colorectum | SER | lipid modification | 47/2897 | 212/18723 | 6.01e-03 | 4.38e-02 | 47 |
GO:0022408 | Colorectum | SER | negative regulation of cell-cell adhesion | 44/2897 | 196/18723 | 6.08e-03 | 4.42e-02 | 44 |
GO:00092251 | Colorectum | SER | nucleotide-sugar metabolic process | 12/2897 | 36/18723 | 6.11e-03 | 4.42e-02 | 12 |
GO:00181961 | Colorectum | SER | peptidyl-asparagine modification | 9/2897 | 24/18723 | 7.19e-03 | 4.99e-02 | 9 |
GO:00182792 | Colorectum | MSS | protein N-linked glycosylation via asparagine | 13/3467 | 23/18723 | 5.21e-05 | 9.31e-04 | 13 |
GO:00181962 | Colorectum | MSS | peptidyl-asparagine modification | 13/3467 | 24/18723 | 9.44e-05 | 1.49e-03 | 13 |
GO:00064871 | Colorectum | MSS | protein N-linked glycosylation | 23/3467 | 65/18723 | 9.47e-04 | 9.54e-03 | 23 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GALNT2 | SNV | Missense_Mutation | c.1354N>G | p.Gln452Glu | p.Q452E | Q10471 | protein_coding | deleterious(0) | possibly_damaging(0.732) | TCGA-66-2742-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
GALNT2 | SNV | Missense_Mutation | novel | c.328G>A | p.Asp110Asn | p.D110N | Q10471 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BA-4077-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cetuximab | PD |
GALNT2 | SNV | Missense_Mutation | novel | c.955G>A | p.Glu319Lys | p.E319K | Q10471 | protein_coding | tolerated(0.21) | benign(0.041) | TCGA-CV-5442-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GALNT2 | SNV | Missense_Mutation | c.796N>A | p.Ala266Thr | p.A266T | Q10471 | protein_coding | deleterious(0.02) | probably_damaging(0.99) | TCGA-CV-7413-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GALNT2 | SNV | Missense_Mutation | novel | c.1406G>A | p.Gly469Glu | p.G469E | Q10471 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-CV-A45W-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GALNT2 | SNV | Missense_Mutation | novel | c.1652G>A | p.Ser551Asn | p.S551N | Q10471 | protein_coding | tolerated(0.21) | benign(0.021) | TCGA-P3-A5QA-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
GALNT2 | SNV | Missense_Mutation | rs376128700 | c.1109N>T | p.Pro370Leu | p.P370L | Q10471 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BR-7851-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GALNT2 | SNV | Missense_Mutation | c.728N>C | p.Glu243Ala | p.E243A | Q10471 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-CG-4437-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
GALNT2 | SNV | Missense_Mutation | novel | c.428C>T | p.Thr143Met | p.T143M | Q10471 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-SW-A7EA-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GALNT2 | SNV | Missense_Mutation | novel | c.250N>A | p.Glu84Lys | p.E84K | Q10471 | protein_coding | tolerated(1) | benign(0) | TCGA-VQ-A923-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2590 | GALNT2 | DRUGGABLE GENOME | atenolol | ATENOLOL |
Page: 1 |